aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded with a mission to transform cutting-edge science into life-saving therapeutics, ADARx Pharmaceuticals is a pioneering genetic medicine company specializing in mRNA base editing. The company focuses on developing a modality-agnostic RNA targeting platform, which includes oligonucleotides for inhibition, degradation, and editing, along with innovative delivery technologies. ADARx aims to address intractable diseases across three primary therapeutic areas, leveraging its multi-faceted RNA targeting platform for wide-ranging therapeutic interventions.
ADARx Pharmaceuticals has attracted notable investors and industry experts who support its groundbreaking work in genetic medicine. The company has achieved significant milestones in advancing its drug platform and building a deep pipeline of potential therapeutics. Its impact is evident in the innovative approaches it brings to the field of genetic medicine, offering new hope for treating previously untreatable conditions through precise mRNA targeting and editing.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private Equity
Main Product(s)
Therapeutics
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Adarx Pharmaceuticals founded?
Adarx Pharmaceuticals was founded in 2019.
Where is Adarx Pharmaceuticals’s headquarters located?
Adarx Pharmaceuticals’s headquarters is located in San Diego, CA, US.
When was Adarx Pharmaceuticals’s last funding round?
Adarx Pharmaceuticals’s most recent funding round was for $200M (USD) in August 2023.
How many employees does Adarx Pharmaceuticals have?
Adarx Pharmaceuticals has 50 employees as of Feb 5, 2024.
How much has Adarx Pharmaceuticals raised to-date?
As of July 05, 2023, Adarx Pharmaceuticals has raised a total of $332M (USD) since Aug 9, 2023.
Add Comparison
Total Raised to Date
$332M
USD
Last Update Aug 9, 2023
Last Deal Details
$200M
USD
Aug 9, 2023
Series C
Total Employees Over Time
50
As of Feb 2024
Adarx Pharmaceuticals Address
5871 Oberlin Drive
suite 200
San Diego,
California
92121
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts